The U.S. Securities and Exchange Commission (SEC) has charged three former executives of Medly Health Inc. with defrauding investors in a $170 million scheme involving fake prescriptions. Additionally, Zymergen Inc., a biotech company, has settled charges with the SEC for misleading IPO investors about its market potential, revenue prospects, and customer pipeline for its product, Hyaline. The SEC also charged senior fund executives and salespeople in connection with a $60 million pre-IPO fraud scheme, where defendants lied to investors about hidden markups and fees and stole millions of dollars in customer funds. In another case, a former Jefferies hedge fund manager is facing a federal criminal probe for allegedly defrauding the fund out of more than $100 million. Lastly, members of an international sextortion ring have been charged with stealing $2 million from victims.